medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (1)


First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder

Nahdi NA, Jo-Ann F, Greanya ED, Jo-Ann H, Tse I, Steinbrecher UP, Erb SR, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 156-160
Archivo PDF: 84.09 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, et al. Severe recurrent cholestatic hepatitis C following orthoptic liver transplantation. Hepatology 1996; 23: 971-6.

  2. Furuta K, Takahashi T, Aso K, Hoshino H, Sato K, Kakita A. Fibrosing cholestatic hepatitis in a live transplant recipient with hepatitis C virus infection: a case report. Transplant Proc 2003; 35: 389-91.

  3. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13: 219.

  4. Fang JW, Wright TL, Lau JY. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993; 342: 1175.

  5. Saleh F, Ko HH, Davis JE, Apiratpracha W, Powell JJ, Erb SR, Yoshida EM. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol 2007; 6: 186-9.

  6. Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphmamide/rituximab for low grade non-Hodgkin’s lymphoma. Eur J Med Res 2008; 13: 483-6.

  7. Lisa RD, James MC. Early histologic changes in Fibrosing cholestatic hepatits C. Liver Transpl 2007; 13: 219-26.

  8. Davies SE, Portmann BC, O’Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological finding after transplantation for chronic hepatitis B infection, including a unique pattern of Fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.

  9. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, et al. Severe recurrent cholestatic hepatitis C following orthoptic liver transplantation. Hepatology 1996; 23: 971-6.

  10. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, Hassoba H, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30: 1513-20.

  11. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202- 10.

  12. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-anaylsis. Liver Transpl 2007; 13: 21-9.

  13. Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, et al. Successful treatment of Fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc 2011; 43: 905-8.

  14. Bolkhir A, Brunt EM, Solomon HS, Hayashi PH. Sustained resolution of Fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy. Liver Transpl 2007; 13: 309-11.

  15. Incivek (Telaprevir) (package insert). Cambridge, Mass: Vertex Pharmaceuticals; 2011.

  16. Victrelis (boceprevir) (package insert). Whitehouse Station, NJ: Merck&Co; 2011.

  17. Bacon BR, Gordon SC, Lawitz E, Marcellin P, et al. Boceprevir for previously treated chronic HCV genotype1 infection. N Engl J Med 2011; 364: 1207-17.

  18. Vierling J, Flamm S, Gordon S, Lawitz E, Bronowicki JP, Davis M, Yoshida E, et al. Efficacy of Boceprevir in Prior Null Responders to Peginterferon/Ribavrin: the PROVIDE Study. Hepatology 2011; 54(Suppl.): 796-77A (Abstract).

  19. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18.

  20. Wilby KJ, Greanya E, Ford JE, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 197-85.

  21. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic hepatitis C genotype 1 infection. N Engl J Med 2011; 364: 1195-20.




2020     |     www.medigraphic.com